SLC5A2 and type 2 diabetes mellitus: An additional meta-analysis of 51 randomized controlled trials including a total of 24,163 people with T2D observed no significant differences between treatment with high- and low-dose SGLT2 inhibitors in terms of renal-related adverse events, although composite renal outcomes were not investigated [46].